CERE

Analyst Note: Cerevel Therapeutics Holdings, Inc. (CERE) Date: 2026-06-13 Current Price: $44.96

1. Structural Readiness

• State: Context-only.
• Aggressive/Pre-Breakout Entry: — (Not recommended as a standalone signal; requires confirmation).
• Current Price: $44.96.
• Extension: — (No extension data provided).
• ATR Context: Current ATR is 1.5% (sub-threshold). This indicates low volatility relative to the historical "sweet spot" (4–6%), suggesting the stock is currently in a consolidation or low-momentum phase rather than a high-velocity expansion.

2. Thesis Layer

• Thesis Classification: Tactical, Setup-Led.
• Secular Exposure: No named secular thesis is attached to this name as of 2026-06-13.
• Judgment Framework: The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the underlying business fundamentals (pipeline execution and financial runway). No macro or thematic tailwinds are currently assigned to this specific setup.

3. Business Overview

• Company Description: Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system (CNS) disorders.
• Business Model: The company operates on a clinical-stage biopharma model, relying on the successful execution of clinical trials to advance its portfolio of proprietary assets toward regulatory approval (NDAs) and commercialization.
• Industry: Biotechnology / CNS Therapeutics.
• Key Assets & Evidence (as of 2026-06-13):
• Tavapadon: A D1/D5 partial agonist for Parkinson's disease. Management previously stated (2023-11-01) an expectation to file two NDAs in 2025 if data were positive. As of mid-2026, the company is expected to be in the post-filing or early commercialization phase for this asset, pending the 2025 filing timeline.
• Emraclidine: An M4-selective PAM for schizophrenia and Alzheimer's disease psychosis. Management (2023-11-01) indicated a 2025 NDA filing timeline contingent on positive data.
• Darigabat: A selective Alpha 2/3/5 GABAA PAM for focal epilepsy and panic disorder.
• Pipeline Expansion: The company profile (2026-06-12) confirms a robust pipeline including:
• CVL-936: Selective dopamine D3-preferring antagonist (Phase I) for substance use disorder.
• CVL-354: Selective kappa-opioid receptor antagonist (MDD and substance use disorder).
• CVL-047: Selective PDE4 inhibitor (MDD and substance use disorder).
• Financial Context: The financial spine (2026-06-12) indicates the company remains in a pre-profitability phase with forward consensus EPS estimates of -2.95 for FY1 and -1.91 for FY2. This confirms the company is burning cash to fund its clinical and regulatory activities.

4. Archetype and Conviction

• Archetype: Quality Compounder (Source: layer_a).
• *Fit:* The company is characterized by a robust, differentiated pipeline in high-value CNS indications (Parkinson's, Schizophrenia, Epilepsy) and a management team that has historically provided clear, timeline-driven guidance (e.g., the 2025 NDA filing targets). The "Quality" aspect stems from the scientific differentiation (e.g., first-in-class D1/D5 partial agonist) and the structured approach to development.
• Valuation & Financials: The company is not yet profitable, with negative EPS consensus for the next two fiscal years. The valuation is likely driven by the probability-weighted value of the upcoming commercial assets (Tavapadon, Emraclidine) rather than current earnings.
• Conviction Stack:
• Thesis Strength: Moderate. The lack of a named secular thesis limits the "macro" tailwind, but the tactical setup is supported by a clear business roadmap.
• Evidence Quality: High. The evidence base includes specific earnings transcripts with clear timelines and a current company profile confirming the pipeline depth.
• Setup Readiness: Partial. The coil is forming, which historically has a ~69% success rate for breakouts, but it is not yet actionable on a conservative basis.
• Rerating Potential: High, contingent on the successful execution of the 2025 NDA filings and subsequent data readouts, which would transition the company from a clinical-stage to a commercial-stage valuation.

5. Invalidations, Strengths, and Gaps

• Gaps in Evidence:
• 2026 Performance Data: While the 2023 transcript provides the roadmap, there is no specific 2026 earnings data or updated financial guidance in the provided evidence block to confirm if the company is on track to meet the 2025 filing targets.
• Cash Runway: The financial spine shows negative EPS but does not explicitly detail the current cash balance or burn rate, which is critical for a pre-profitability biotech.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management's clear 2025 NDA filing timeline for Tavapadon and Emraclidine; robust pipeline including CVL-936, CVL-354, and CVL-047; forming coil structure with price holding above support. Key risks: Company remains unprofitable with negative EPS consensus; low ATR (1.5%) indicates weak momentum and potential for extended consolidation; binary nature of clinical/regulatory outcomes for CNS assets. Sizing hint: Position size should be conservative given the "forming" status and lack of confirmed breakout; treat as a satellite holding pending structural confirmation. Expected horizon: 3 to 6 months for a potential structural breakout or invalidation.